KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Financing Activities (2019 - 2025)

Royalty Pharma's Cash from Financing Activities history spans 6 years, with the latest figure at -$299.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 16.14% year-over-year to -$299.6 million; the TTM value through Dec 2025 reached -$1.8 billion, down 605.16%, while the annual FY2025 figure was -$1.2 billion, 428.39% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$299.6 million at Royalty Pharma, up from -$941.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1.2 billion in Q2 2024 and bottomed at -$941.3 million in Q1 2025.
  • The 5-year median for Cash from Financing Activities is -$227.5 million (2021), against an average of -$124.8 million.
  • The largest annual shift saw Cash from Financing Activities soared 433.32% in 2024 before it plummeted 344.01% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$198.1 million in 2021, then crashed by 34.07% to -$265.6 million in 2022, then crashed by 30.67% to -$347.0 million in 2023, then rose by 25.66% to -$258.0 million in 2024, then decreased by 16.14% to -$299.6 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Cash from Financing Activities are -$299.6 million (Q4 2025), -$941.3 million (Q1 2025), and -$258.0 million (Q4 2024).